FDA
-
-
-
-
-
-
-
ProQR Announces Second Quarter 2022 Operating and Financial Results
-
-
-
-
-
-
-
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
-
-
-
-
-
-
-
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
-
-
-
-
-
-
-
ProQR Announces Virtual Presentation at EURETINA 2021
-
-
-
-
-
-
-
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
-
-
-
-
-
-
-
After-Hours Stock Movers 03/30: (SURF) (CASI) (CHWY) Higher; (NMTR) (OSMT) (BB) Lower (more...)
-
-
-
-
-
-
-
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

